Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases

Authors

Sulena Shrestha, STATinMED Research/SIMR, Inc.
Raymond Miao, Sanofi US
Li Wang, STATinMED Research/SIMR, Inc.Follow
Jingdong Chao, Regeneron Pharmaceuticals, Inc.
Huseyin Yuce, CUNY New York City College of TechnologyFollow
Wenhui Wei, Regeneron Pharmaceuticals, Inc.

Document Type

Article

Publication Date

Summer 7-13-2017

Abstract

Comparative data on the burden of atopic dermatitis (AD) in adults relative to the general population are limited. We performed a large-scale evaluation of the burden of disease among US adults with AD relative to matched non-AD controls, encompassing comorbidities, healthcare resource utilization (HCRU), and costs, using healthcare claims data. The impact of AD disease severity on these outcomes was also evaluated.

Comments

This work was originally published in Advances in Therapy, available at doi:10.1007/s12325-017-0582-z.